Introduction

On 6 October 2025, the board of directors resolved to apply for a voluntary delisting of the Company’s shares from Spotlight Stock Market, subject to approval by the general meeting, and on 21 October 2025, the general meeting of the Company approved that the Company shall apply for a voluntary delisting of the Company’s shares from Spotlight Stock Market. Therefore, on 7 January 2026, the Company will submit a request to Spotlight Stock Market for a voluntary delisting from Spotlight Stock Market, and provided that the request is approved, the last day of trading of the Company’s shares on Spotlight Stock Market is 22 January 2026. Please refer to the press release "DanCann Pharma A/S has resolved to apply for delisting from Spotlight Stock Market, subject to approval by the general meeting" of 6 October 2025 for further information.

A total of 1,224,993 outstanding warrants in the Company issued pursuant to and on the terms set out in Schedule A of the articles of association are exercisable in the period from 12 January 2026 to 1 February

2026, except that in the event of an "Exit" ahead hereof, all warrants are exercisable prior to such Exit. A delisting of the Company’s shares is deemed an "Exit" under the warrant terms, and consequently the Company hereby gives notice (Exit Notice) to all warrant holders that their warrants are exercisable in an extraordinary exercise period running from today and until (and including) 12 January 2026.

Each warrant carries the right to subscribe for 1 share of nominally DKK 1 at an exercise price of DKK 2.60 per share. In the event of full exercise of all such warrants, the share capital of the Company is increased by nominally DKK 1,224,993.

List of warrants

Below is a list of the warrants that are exercisable as a result of the delisting application:

A warrant holder can exercise either all or a part of its warrants. If a warrant holder wishes to exercise warrants, please give notice hereof by way of email to info@dancann.com, indicating the number of warrants exercised, no later than by 15:00 (CET) on 12 January 2026. By submitting an exercise notice, the warrant holder will receive payment instructions with respect to payment of the subscription amount.

Following expiry of the exercise period, the Company will disclose the results.

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.

Contact

DanCann Pharma A/S

Rugvænget 5, DK-6823 Ansager, Denmark

E-mail: info@dancann.com

Website: www.dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company''s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company''s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company''s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company''s public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.